PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA
Clinical trials for PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare blood cancers: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with certain slow-growing but incurable blood cancers (T/NK-cell lymphomas) that have not responded to standard treatment. About 48 adults will receive the drug to see if it shrinks tumors and how safe it is. The goal is to co…
Matched conditions: PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Massive T-Cell lymphoma database aims to unlock better treatments
Knowledge-focused Recruiting nowThis study is creating a large database of information from 1,000 people with T-cell lymphoma. Researchers will collect medical records and tumor samples to learn more about the disease and how to improve care. No new treatments are being tested; the goal is to gather data for fu…
Matched conditions: PRIMARY CUTANEOUS ACRAL CD8-POSITIVE T-CELL LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC